GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
GCTKGlucoTrack(GCTK) Newsfilter·2024-06-05 20:30

Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet and less intrusive glucose monitoring for people with diabetes Rutherford, NJ, June 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, ...